

PERSONAL COVID-BP

Closed Loop Medicine

The PERSONAL COVID BP study, run by digital therapeutics company Closed Loop Medicine (CLM), aimed to validate the development of a novel combination product that links a drug to a smart phone app, enabling remote management of patients with hypertension during the COVID-19 pandemic.



Key Outcomes



21 days

to meet enrollment target,
5 months earlier than target.



1757

patients engaged.



213

patients referred.



73%

of patients referred were enrolled.

Overview & Objectives

Hypertension may have a significant impact on the severity of COVID-19 and can be a considerable risk factor for the likelihood of hospitalisation. Furthermore, patients with hypertension require long term healthcare management, which was a challenge throughout the pandemic with the requirement for social distancing, as well as redirection of care towards patients with COVID-19.

The PERSONAL COVID BP clinical trial, run by digital therapeutics company Closed Loop Medicine (CLM), aimed to validate the development of a novel combination product that links a drug to a smart phone app, enabling remote management of patients with hypertension during the COVID-19 pandemic.

CLM secured funding from Innovate UK Precision Medicine Accelerator to run the study in partnership with Queen Mary University London for CLM's integrated precision care solution for patients with hypertension.

The study aimed to investigate whether the product could enable patients to personalise and optimise their healthcare regimen to treat hypertension. The technology allowed patients shielding from COVID-19 to control their blood pressure remotely in a home setting environment.

Our Approach

Despite using radio advertising and other methods to increase enrollment in the study, CLM had been struggling with their overall recruitment rates and were looking to further improve patient participation.

Working in partnership with CLM and the team at Queen Mary University London, uMed identified and pre-screened eligible patients using primary care health records and reached out via SMS on behalf of the patient's recognised healthcare provider. This process invited only the most appropriate patients to participate in the study, reducing unnecessary burden on patients, site staff and the sponsor.

uMed was key to the PERSONAL COVID BP study exceeding recruitment targets, enabling CLM to enroll the most relevant patients needed to move the study into its delivery phase.

“ Sites saw a rapid increase when using uMed to find and contact patients, versus them recruiting patients manually. Patients contacted via SMS on behalf of their healthcare provider were far more engaged than those recruited to the study via the traditional enrollment methods. ”

Closed Loop Medicine



Read the full news story here:

Closed Loop Medicine announces completion of precision medicine clinical trial for patients with high blood pressure

uMed+

To understand how uMed can access the custom data and insights required to accelerate your research, contact us at hello@umed.io.